Voriconazole In An Infant With Cryptococcal Meningitis
Yin-zhong Shen,Jiang-rong Wang,Hong-zhou Lu
DOI: https://doi.org/10.1097/00029330-200802010-00024
IF: 6.133
2008-01-01
Chinese Medical Journal
Abstract:Cryptococcus neoformans (C. neoformans) is the most common cause of fungal meningitis worldwide.1 Cryptococcal meningitis is an opportunistic infection commonly found in immunocompromised hosts, especially HIV-infected adults. It also occurs in apparently immunocompetent individuals. Rarely has it been reported in children, and it is almost nonexistent in infants.2 Voriconazole is a member of a second generation of antifungal triazoles with broad spectrum antifungal activity, oral and parenteral bioavailability and a favorable safety profile in adults.3 This patient shows improved in vitro activity against C. neoformans when compared to fluconazole and it has been used successfully in about half the patients with refractory cryptococcosis.4 However, the efficacy and safety of voriconazole as a antifungal agent in children with cryptococcal meningitis have not been well assessed. This report described cryptococcal meningitis in a 13-day-old premature neonate who recovered without overt toxicity after voriconazole was added to an antifungal regimen that included amphotericin B and flucytosine. We focused on the response of this child with cryptococcal meningitis to voriconazole. CASE REPORT A prematurely born, 4-month-old infant was transferred to our hospital because of intermittent fever. The infant was born by vaginal delivery from a healthy mother at 34-week gestation on March 8, 2006 with a birth weight of 2600 g. After birth, he was transferred to a local county children hospital for further care. Three days after the birth, CT scan of the brain showed encephalic hemorrhage. Intermittent fever of 37.8-38.8°C rectally started on March 20 and persisted until April 29. A generalized convulsion started on March 20 and persisted for three days. A lumbar puncture was performed on March 20, which showed that his cerebrospinal fluid (CSF) was positive for fungi (strain identification was not done). Thus the patient was diagnosed with fungal meningitis infection and intravenous fluconazole (12 mg·kg-1·d-1) was administered. However, his condition was not improved after the treatment. On April 15, the infant was transferred to a hospital in Beijing. CSF examination showed a cryptococcal antigen titer of 1/2, but the stains and cultures in CSF were negative for bacteria and C. neoformans. The concentrations of protein, glucose, and chloride in the CSF were 1.241 g/L, 1.8 mmol/L, and 127 mmol/L, respectively. Serologic testing for antibodies to toxoplasma, HIV, cytomegalovirus, varicella-zoster, Epstein-Barr, rubella, Coxsackie, and herpes simplex type 1 and 2 viruses was negative. Therefore, intravenous fluconazole (12 mg·kg-1·d-1) was restarted and continued for 14 days. Afterwards, the infant recovered without either fever or convulsion, and was discharged from the hospital on April 30. Nevertheless, 2 days after the discharge the infant was admitted to another children hospital because of fever. On admission, CSF examination showed protein 1.4 g/L, glucose 0.92 mmol/L, and chloride 116 mmol/L. Intravenous amphotericin B 0.5 mg·kg-1·d-1 combined with fluconazole 12 mg·kg-1·d-1 was administered and continued for 21 days until his fever stopped. However, the infant then developed vomiting and diarrhea, and was transferred to our hospital on July 5. On examination, he weighed 6500 g, with a body temperature of 37.0°C, pulse 120 beats/min, blood pressure 94/57 mmHg, and respiration 30 breath/min. Physical examination showed that the neck was soft, the heart and lungs were normal, and the abdomen was soft with the liver 1.5 cm below the right costal margin. CSF obtained on July 6 showed 248 white blood cells/μl with 68% lymphocytes, protein 660 mg/L, glucose 1.2 mmol/L, and chloride 127 mmol/L. Since stains and cultures in CSF were negative for bacteria and C. neoformans, the patient was monitored closely without special treatment. The infant had no fever or convulsion until 11 days after the admission, when intermittent fever of 38.0-38.8°C rectally occurred. Thus, treatment with intravenous norvancomycin (16 mg·kg-1·d-1) and fosfomycin (100 mg·kg-1·d-1) was started. Whereas, after 6-day treatment, the infant remained febrile; CSF protein peaked at 2.8 g/L and CSF glucose decreased to 0.1 mmol/L. Accordingly, therapeutic regimen was changed to intravenous liposomal amphotericin B (10 mg/d) plus oral flucytosine (100 mg·kg-1·d-1), and persisted till August 16. After the treatment, his condition was improved, CSF obtained on August 9 showed 400 white blood cells/μl with 42% lymphocytes, protein 2.4 g/L, glucose 1.5 mmol/L, and chloride 123 mmol/L. On August 16, the infant was transferred to another children hospital in Shanghai to receive intrathecal injections of amphotericin B (0.1 mg twice a week). Meanwhile, intravenous liposomal amphotericin B (10 mg/d) and oral flucytosine (100 mg·kg-1·d-1) were added. In this hospital, lumbar puncture found that the stains and cultures in CSF were positive for C. neoformans. Therefore, the diagnosis of cryptococcal meningitis was confirmed. After receiving intrathecal injections of amphotericin B for 6 times, the infant’s condition was improved. CSF obtained on September 6 showed 60 white blood cells/μl, glucose 1.6 mmol/L, chloride 124 mmol/L, and protein 1.5 g/L. Then, the patient was sent back to our hospital on September 7, when he was 5 months old weighing 8500 g. Treatment with intravenous liposomal amphotericin B (10 mg/d) and oral flucytosine (100 mg·kg-1·d-1) were used for 4 days, and then oral voriconazole (7 mg/kg every 12 hours) alone was given for 20 days (oral informed consent was given by his parents before using voriconazole). On October 1, the infant was discharged on request, and was administered to continue oral voriconazole (7 mg/kg every 12 hours). Evaluation of the efficacy and potential adverse effects of voriconazole included tests of electrolytes, liver and renal functions, peripheral blood, and CSF. While on voriconazole, the patient’s condition was improved gradually with weight gaining and the disease-related clinical symptoms and signs gently disappeared. The results of CSF analysis gradually recovered to the normal range. Stains, fungal cultures and latex agglutination tests of CSF were negative throughout voriconazole treatment. The values of laboratory tests including electrolytes, renal function and transaminases were within a normal range during the treatment. His alkaline phosphatase and lactate dehydrogenase levels peaked at 437 and 274 U/L, respectively, and hemoglobin and hematocrit decreased to 100 g/L and 30.3%. All the values recovered to the normal range by the date of discharge. Voriconazole was discontinued on November 27, 2006 when recovery was thought to be achieved. The patient is doing well until April 1, 2007. DISCUSSION A relatively small number of cases of cryptococcal meningitis in neonates have been reported, most of them were infants born prematurely.5-7 In this report, the neonate was anti-HIV-negative and had no underlying illnesses. The source and mode of entry of C. neoformans in this neonate was unknown. Optimal current therapy for cryptococcal meningitis includes amphotericin B 0.7-1.0 mg/kg/d plus flucytosine 100 mg/kg/d for 2 weeks, followed by fluconazole 400 mg/d for 8 weeks and 200 mg/d thereafter.8 Itraconazole may be substituted for fluconazole in patients who can not tolerate the agent.9 Voriconazole has an activity against Cryptococcus spp. in vitro and thus might be an alternative. To our knowledge, this is the first report of voriconazole as a consolidation therapy successfully used in an infant with cryptococcal meningitis, although not the first report of the drug used in a child.10 In this case, on September 11, 2006, we initiated treatment with voriconazole alone, and the infant responded promptly and then recovered completely. Several factors are likely to have contributed to his prolonged hospitalization. First, the definitive diagnosis was delayed. Second, suboptimal initial therapy may have been a contributing factor. The patient received antifungal treatment with fluconazole initially, which was discouraged by the Infectious Diseases Society of America’s practice guidelines.9 The adverse effects of voriconazole include fever, gastrointestinal symptoms, headache, hypotension, visual disturbances, Stevens Johnson syndrome, toxic epidermal necrolysis, pancreatitis, hepatitis, and jaundice.11 Visual disturbances have been reported in 45% of patients after using voriconazole in clinical trials.11 Walsh and colleagues10 had described the efficacy and safety of the drug in children. In their study, 58 patients with invasive fungal infections were enrolled, and 26 of them (45%) had a complete or partial response at the end of the therapy. The most commonly reported adverse events included elevation of hepatic transaminases or bilirubin (n=8), skin rash (n=8), abnormal vision (n=3), and photosensitivity reaction (n=3). Liver function should be monitored before treatment, and then at a 2- to 4-week intervals. In our case, we did not observe any serious complications caused by voriconazole. Since the patient was less than one year old during treatment, we could not fully assess the impact of voriconazole on his vision, which needs further research. The patient did have mildly elevated alkaline phosphatase and lactate dehydrogenase, and experienced mild anemia while receiving voriconazole. Given that the patient had been treated with amphotericin B combined with flucytosine before voriconazole treatment, we can not attribute his anemia solely to voriconazole. Although known to be the adverse effects of voriconazole, the abnormalities observed in this patient did not require a change of therapy. In conclusion, we consider that voriconazole can be administered safely to infant and lead to a clinical improvement. Although we cannot recommend the use of voriconazole in pediatric patients based on the single case, our experience with this patient suggests that voriconazole may be considered in infant with cryptococcal meningitis. Further research is needed to fully assess the clinical potential of voriconazole for cryptococcal meningitis in young children.